December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

33.16 -6.66 (-16.73%)
Streaming Delayed Price Updated: 3:13 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Corcept Therapeutics Return On Capital Employed Overview ↗
  
Via Benzinga
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More ↗
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Our 7 Top Biotech Stock Picks for 2023 ↗
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
News headline image
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Therapeutics Provides Miricorilant Clinical Development Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Therapeutics's Earnings: A Preview ↗
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
These 3 Stocks Are Winning the Bear Market -- Here's How ↗
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies. 
Via The Motley Fool
News headline image
7 Under-the-Radar Stocks With 100% Upside Potential ↗
If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully. 
Via InvestorPlace
News headline image
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
News headline image
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
3 Biotech Stocks Outperforming a Bear Market ↗
These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy. 
Via InvestorPlace
News headline image
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8% ↗
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
News headline image
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating ↗
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier. 
Via Investor's Business Daily
News headline image
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 ↗
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. 
Via Investor's Business Daily
News headline image
Kura Oncology Stock Scores Rising Relative Strength ↗
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier. 
Via Investor's Business Daily
News headline image
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study ↗
Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.